NTLA

Intellia Therapeutics, Inc. (NTLA) - Q3 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2025. Intellia Therapeutics is a clinical-stage gene editing company focused on developing CRISPR-based therapies for genetic diseases (in vivo) and immuno-oncology/autoimmune diseases (ex vivo). The company operates as a single segment and has not yet generated revenue from product sales, relying on collaboration agreements and equity financing.

Key Financial Metrics

Note: Total liquidity as of September 30, 2025, is approximately $670 million. The company reported no debt obligations other than operating lease liabilities.

Material Changes vs. Prior Period

• Revenue: Q3 2025 revenue increased 51% year-over-year to $13.8 million, driven primarily by cost reimbursements from the Regeneron collaboration. For the nine months ended September 30, revenue was flat at $44.7 million, impacted by the absence of a $21.0 million one-time revenue recognition from an AvenCell intra-entity profit adjustment recorded in the prior year.
• Expenses: Total operating expenses decreased 19% in Q3 and 13% for the nine-month period compared to 2024. This reduction is attributed to a strategic restructuring in January 2025, which included a 27% workforce reduction, resulting in lower employee-related expenses and stock-based compensation.
• Net Loss: Net loss narrowed significantly in both Q3 and the nine-month period due to reduced operating expenses and a favorable change in the fair value of investments.
• Liquidity: Cash and marketable securities decreased from $793 million at year-end 2024 to $670 million at September 30, 2025, primarily due to operating cash burn and lease modification payments.

Guidance, Outlook, and Risks

• Clinical Hold (Critical Risk): On October 29, 2025, the FDA placed a clinical hold on the IND applications for the MAGNITUDE and MAGNITUDE-2 Phase 3 trials for nex-z (ATTR amyloidosis). This followed a report of Grade 4 liver transaminase elevations and increased bilirubin in a patient who subsequently passed away. The company has suspended milestone guidance for nex-z pending resolution.
• Lonvo-z Progress: Enrollment for the Phase 3 HAELO trial for lonvo-z (Hereditary Angioedema) was completed in September 2025. Topline data is expected by mid-2026, with a potential U.S. launch in the first half of 2027.
• Liquidity Outlook: Management expects current cash, cash equivalents, and marketable securities to fund operations into mid-2027, excluding potential milestone payments.
• Restructuring: The company terminated the SparingVision and ReCode collaboration agreements in late 2025 as part of its portfolio prioritization strategy.
• Legal Proceedings: The company is involved in patent infringement litigation with BlueAllele Corp. and a securities class action lawsuit (Gonzalez v. Intellia) regarding statements made about the NTLA-3001 program.

Investor Verification Checklist

• FDA Clinical Hold Status: Verify the timeline and conditions for lifting the clinical hold on the nex-z Phase 3 trials and the outcome of the safety investigation regarding the patient death.
• Lonvo-z Data Readout: Monitor the mid-2026 topline data release for the HAELO Phase 3 trial, which is the company's nearest potential commercial catalyst.
• Cash Burn Rate: Assess whether the current liquidity runway of ~21 months is sufficient given the uncertainty surrounding the nex-z program and potential need for additional capital raises.
• Regeneron Collaboration: Review the terms and future revenue potential of the Regeneron agreements, which remain the primary source of non-dilutive funding.
• Lease Obligations: Confirm the financial impact of the new Tech Square lease and the termination of the Winter Street lease, including the $78 million in lease modification payments.